Corbus Pharmaceuticals Holdings, Inc. CRBP
3.39 USD -0.02 (-0.59%)
Regular-session close
3.67 +0.28 +8.38%
After hours · Nov 13, 7:44 PM ET
3.27 Day range 3.53
2.86 52-week range 12.15
- YTD
- -58.35%
- 1 year
- -69.38%
News
benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $23 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $24 to $23.
benzinga.com RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33 RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.
benzinga.com Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27 Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.
benzinga.com Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.20) by 50.83 percent. This is a 4.74 percent increase over…
globenewswire.com Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of…
marketbeat.com Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data Corbus Pharmaceuticals NASDAQ: CRBP has started a Phase 3 study of its cancer drug CRB-701 and expects an exploratory readout from a separate frontline combination study in the first quarter of next…benzinga.com Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase…
benzinga.com HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
benzinga.com Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…benzinga.com Market-Moving News for September 14th GLW: -8% | Corning shares are trading lower after the company announced a $2 billion offering. ELMT: 49% | Elmet Group Lands $450M US Government Investment To Expand Tungsten Manufacturing, To Invest…
benzinga.com Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric…
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticalsbenzinga.com Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host…
benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
benzinga.com HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.
benzinga.com Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over…
benzinga.com Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical…
benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.
benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.
benzinga.com Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30 Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session benzinga.com HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $40 price target.
benzinga.com Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug Conjugate Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forwardConfirmed ORR of 42.9%…
benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $40 to $44.
benzinga.com Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell Carcinoma Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team…
benzinga.com Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33 Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $36 to $33.
benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $54 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $57 to $54.
benzinga.com Guggenheim Reiterates Buy on Corbus Pharmaceuticals, Maintains $45 Price Target Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $45 price target.
benzinga.com Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over…
benzinga.com Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45 Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.
benzinga.com Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Roku, SPS Commerce, Newell Brands And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga.com Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Cannabis Stock Movers For July 15, 2025
benzinga.com Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 9, 2025
benzinga.com Marijuana Stock Movers For July 2, 2025
benzinga.com Cannabis Stock Movers For June 30, 2025
benzinga.com Cannabis Stock Gainers And Losers From June 25, 2025
benzinga.com Marijuana Stock Movers For June 23, 2025
benzinga.com Cannabis Stock Gainers And Losers From May 19, 2025
benzinga.com Marijuana Stock Movers For May 12, 2025
benzinga.com Marijuana Stock Movers For May 8, 2025
benzinga.com Cannabis Stock Gainers And Losers From May 6, 2025
